Trial Profile
Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2015
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics
- 04 Apr 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
- 08 Oct 2013 New trial record